Integrating p53 status determined by IHC with the traditional clinicopathological features in patients with HR-positive/Her2-negative breast tumors can be a valuable tool in the hands of the clinician in the decision of the most appropriate therapy, particularly in patients with early breast cancer and null p53 expression. This evidence concerns the gene TP53 and breast neoplasm.